These observations suggest a previously unanticipated mechanism contributing to the pathophysiology of obesity in which DIO disrupts the uroguanylin gut–brain endocrine axis regulating feeding, energy homeostasis and metabolism. Here, GUCA2B is linked to obesity disorder.